Enterococcus faecium R0026 Combined with Bacillus subtilis R0179 Prevent Obesity-Associated Hyperlipidemia and Modulate Gut Microbiota in C57BL/6 Mice

J Microbiol Biotechnol. 2021 Feb 28;31(2):181-188. doi: 10.4014/jmb.2009.09005.

Abstract

Bacillus subtilis and Enterococcus faecium are commonly used probiotics. This study aimed to identify the effect of live combined Bacillus subtilis R0179 and Enterococcus faecium R0026 (LCBE) on obesityassociated hyperlipidemia and gut microbiota in C57BL/6 mice. Forty male C57BL/6 mice were divided into four groups: normal group (N group), model group (M group), low-dose group (L group), and high-dose group (H group). Mice were gavaged with LCBE at 0.023 g/mice/day (L group) or 0.23 g/mice/day (H group) and fed with a high-fat diet for 8 weeks. In vitro E. faecium R0026 showed an ability to lower the low-concentration of cholesterol by 46%, and the ability to lower the highconcentration of cholesterol by 58%. LCBE significantly reduced the body weight gain, Lee index, brown fat index and body mass index of mice on a high-fat diet. Moreover, LCBE markedly improved serum lipids (including serum triglyceride, total cholesterol, low-density lipoprotein and highdensity lipoprotein) while also significantly reducing liver total cholesterol. Serum lipopolysaccharide and total bile acid in L and H groups decreased significantly compared with M group. PCR-DGGE analysis showed that the composition of gut microbiota in the treatment groups was improved. Akkermansia muciniphila was found in H group. The PCA result indicated a similar gut microbiota structure between LCBE treatment groups and normal group while the number of bands and Shannon diversity index increased significantly in the LCBE treatment groups. Finally, qPCR showed Bifidobacterium spp. increased significantly in H group compared with M group, LCBE alleviated liver steatosis and improved brown adipose tissue index.

Keywords: Adiposity; inflammation; microflora; probiotics; serum lipids.

MeSH terms

  • Animals
  • Bacillus subtilis / physiology*
  • Cholesterol / metabolism
  • Enterococcus faecium / physiology*
  • Gastrointestinal Microbiome / drug effects*
  • Humans
  • Hyperlipidemias / etiology
  • Hyperlipidemias / metabolism
  • Hyperlipidemias / microbiology
  • Hyperlipidemias / prevention & control*
  • Lipid Metabolism / drug effects
  • Liver / drug effects
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Obesity / complications*
  • Probiotics / administration & dosage*
  • Weight Gain / drug effects

Substances

  • Cholesterol